Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 12/20 | 1.00 |
| ▸ | STAT1 | P42224 | 1/20 | 1.00 |
| ▸ | STAT4 | Q14765 | 1/20 | 1.00 |
| ▸ | STAT5A | P42229 | 2/20 | 0.44 |
| ▸ | STAT5B | P51692 | 2/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 4/20 | 0.40 |
| ▸ | BIRC3 | Q13489 | 4/20 | 0.40 |
| ▸ | BIRC2 | Q13490 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30308610 | 1.00 | STAT3 (1.00) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL22468771 | 1.00 | STAT3 (1.00) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL30308498 | 1.00 | STAT3 (1.00) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL25210237 | 1.00 | STAT3 (1.00) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL30308404 | 1.00 | STAT3 (1.00) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL25210244 | 1.00 | STAT3 (1.00) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL25199341 | 1.00 | STAT3 (0.99) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL25265848 | 1.00 | STAT3 (0.99) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL30308563 | 1.00 | STAT3 (0.99) | STAT3STAT1STAT4STAT5ASTAT5B | |
| SCHEMBL25217109 | 0.98 | STAT3 (0.97) | STAT3STAT1STAT4STAT5ASTAT5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245413-A1 | IDENTIFICATION OF HIGH MORTALITY SUB-PHENOTYPES OF PEDIATRIC MULTIPLE ORGAN DYSFUNCTION SYNDROME (MODS) FOR MANAGEMENT AND TREATMENT THEREOF | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-11-27 | — | — | WO | claimed |
| CN-119091978-A | Virtual screening method and application of STAT3 inhibitor with anti-tumor efficacy | 东海实验室 | 2024-12-06 | — | — | CN | claimed |
| WO-2024220575-A2 | REGULATING DISEASE OR DISORDER CHARACTERIZED BY ESOPHAGEAL EPITHELIAL PROLIFERATION THROUGH SECRETED FRIZZLED-RELATED PROTEIN 1 (SFRP1) | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-10-24 | — | — | WO | claimed |
| CN-116218825-A | Penicillium sclerotium histone deacetylase encoding gene PsHOS2 and application thereof | 山东省科学院生物研究所 | 2023-06-06 | — | — | CN | claimed |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-04 | — | — | US | claimed |
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743080-A2 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-122029273-A | Compositions and methods for activating immune cells | MDX管理有限责任公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12624038-B2 | Molecules and methods related to treatment of uncontrolled cellular proliferation | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2026090245-A1 | USE OF RAS INHIBITORS FOR TREATING CANCER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090127-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090116-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2023068278-A1 | METHOD FOR IDENTIFYING PROTEIN THAT IS UBIQUITINATED VIA TARGETED PROTEIN DEGRADATION INDUCER | 国立大学法人北海道大学 | 2023-04-27 | — | — | WO | disclosed |
| US-20230083015-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | UNIV MICHIGAN REGENTS (US) | 2023-03-16 | — | — | US | disclosed |
| US-20220331390-A1 | EXOSOME-BASED CANCER ASSAYS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-10-20 | — | — | US | disclosed |
| WO-2022216765-A1 | EXOSOME-BASED CANCER ASSAYS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220251097-A1 | MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2022-08-11 | — | — | US | disclosed |
| CN-114269763-A | Small molecule degradant for STAT3 | 美国密歇根州立大学试剂中心 | 2022-04-01 | — | — | CN | disclosed |
| EP-3946619-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | The Regents Of The University Of Michigan (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020198435-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251097-A1 | MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION | MKI67, BCL2, PCNA | STAT3 238/4885STAT1 370/4885STAT4 815/4885 |
| US-20230083015-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | STAT1, STAT3, JAK2 | STAT3 2/4885STAT1 1/4885STAT4 6/4885 |
| US-12624038-B2 | Molecules and methods related to treatment of uncontrolled cellular proliferation | CCNC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MKI67 | STAT3 1760/4885STAT1 1815/4885STAT4 2243/4885 |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | HLA-DRB1, CD74, HLA-C | STAT3 2125/4885STAT1 893/4885STAT4 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.